Patient-derived tumoroids, also known as cancer organoids, hold potential as cost-effective models for cancer immunotherapy research. Patient-derived tumor models, which mimic the tumor micr...
Acute coughing is one of the most common reasons for consulting in primary care thus driving considerable antibiotic use and health-care costs. Currently, identification of microbial etiolog...
Epigenetic modifications such as DNA methylation have long shown promise as potential biomarkers to diagnose and guide treatment of many human diseases, including multiple types of cancers....
Embark on an enlightening journey through the intricate landscape of loop-mediated isothermal amplification (LAMP) technology. Unveil the ingenious mechanism of rapid DNA amplification under...
Embark on an enlightening journey through the intricate landscape of loop-mediated isothermal amplification (LAMP) technology. Unveil the ingenious mechanism of rapid DNA amplification under...
OCT 10, 2023 | 10:00 AM
C.E. CREDITS
For patients with advanced non-small cell lung cancer (NSCLC), tissue samples are typically small biopsies. These samples undergo standard of care evaluation for >10 biomarkers to identif...
Numerous studies have shown that homologous recombination deficiency (HRD) is a genome-wide biomarker present in high grade ovarian and breast cancers. A cancer therapeutic class, PARP inhib...
In June 2022, the ICH released the first draft of its harmonized global Drug Interaction Studies Guideline (M12). The guideline is the result of several meetings of the Expert Working Group...
Numerous studies have shown that homologous recombination deficiency (HRD) is a genome-wide biomarker present in high grade ovarian and breast cancers. A cancer therapeutic class, PARP inhib...
OCTOBER 05, 2023 2:00 PM ET
In this session we will help you gain an understanding of a Class II BSC's role in the rapidly growing cell and gene therapy market. We will cover......
OCT 05, 2023 | 1:00 AM
C.E. CREDITS
Organoids continue to gain traction in drug discovery efforts as they offer a more biologically relevant disease model than traditional approaches. But they aren't without challenges. Jo...
OCT 04, 2023 | 10:00 AM
C.E. CREDITS
Current clinical methods used to identify epithelial ovarian cancer are often too late – when the cancer is at an advanced stage, leaving the patient with limited therapeutic options....
Join this year's poster presenters in the Poster Hall during the Poster Networking Hour, Wednesday, September 20th, from 10:00 AM –11:00 AM PDT , to chat live about their posters a...